GLP-1 step therapy exception: document contraindication and prior-therapy failure

Most GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Rybelsus, Saxenda — require prior authorization, and a large share of commercial and Medicaid payers layer step therapy on top of PA. Step therapy forces the patient to try — and fail — a preferred medication before the plan covers the requested drug. For GLP-1s, step therapy commonly requires trying metformin first, then a cheaper GLP-1, before gaining access to a non-preferred or higher-cost agent. When a patient cannot or should not follow that sequence, the provider must file a step therapy exception with documentation of contraindication, intolerance, or therapeutic failure.

This guide maps GLP-1 step therapy requirements across major payer segments, details what documentation each exception type demands, and provides a practical exception workflow. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.

Quick answer

Key regulatory context:

• CMS-0057-F (effective January 1, 2026): Medicare Advantage, Medicaid, and QHP plans must shorten PA timelines to 72 hours expedited / 7 days standard, and must publicly report PA metrics including denial rates
• AHIP voluntary pledges (effective January 1, 2026): Participating insurers must reduce the number of claims requiring PA, honor existing PAs for 90 days when patients switch plans, and provide clear explanations for PA determinations
• Pennsylvania Medicaid (effective January 1, 2026, revised March 2, 2026): All GLP-1 prescriptions require PA; non-preferred GLP-1s require documented therapeutic failure of preferred agents at maximum FDA-approved doses

Who this is for

• Prescribers and clinic staff navigating GLP-1 step therapy requirements and exceptions
• Benefit verification specialists and hub teams documenting prior-therapy failure for GLP-1 PA submissions
• Market access teams tracking payer step therapy policies for GLP-1 formulary positioning
• Patients seeking to understand why their plan requires trying a different GLP-1 first

Source standard

Every fact in this guide is sourced from payer clinical policy bulletins, state Medicaid PA handbooks (particularly Pennsylvania's January/March 2026 GLP-1 PA guidelines), CMS regulatory documents, published research in the Journal of General Internal Medicine, and industry reports from IntuitionLabs, KFF, and Truveris dated 2025–2026. Step therapy policies vary by plan, state, and employer. Always verify current requirements by calling the member services number on the patient's insurance card or checking the payer's provider portal.

How GLP-1 step therapy works

What step therapy requires

Step therapy — also called "fail first" — is a form of utilization management where the payer requires the patient to try a preferred (usually less expensive) medication before covering a non-preferred or higher-tier drug. For GLP-1 receptor agonists, step therapy typically operates at two levels:

1. First-line therapy requirement: Try metformin, an SGLT-2 inhibitor, or another oral antidiabetic before any GLP-1. This is common for type 2 diabetes GLP-1 prescriptions.
2. Within-class step therapy: Try a preferred GLP-1 (typically the one with the lowest net cost to the plan) before a non-preferred GLP-1. For example, Ozempic may be preferred over Mounjaro on a plan formulary, requiring documented failure of Ozempic before Mounjaro is covered.

Pennsylvania's 2026 Medicaid GLP-1 PA handbook explicitly codifies within-class step therapy. For a non-preferred GLP-1 for diabetes, the PA requires "a history of therapeutic failure of or a contraindication or an intolerance to the maximum FDA-approved dose of the preferred GLP-1 Receptor Agonists." For weight management, the requirements are even more layered: Mounjaro requires failure of both Ozempic and Wegovy at maximum doses; Zepbound requires failure of Ozempic, Wegovy, and Mounjaro.

Why payers use step therapy for GLP-1s

GLP-1 receptor agonists are among the most expensive drug classes in the United States, with monthly list prices ranging from approximately $800 to $1,469 per patient. According to KFF data, GLP-1s accounted for over 8% of all Medicaid prescription drug spending before rebates in 2024, up from 1% in 2019, despite representing only about 1% of prescriptions. Step therapy allows payers to manage costs by directing patients to the lowest-net-cost GLP-1 first while still providing a pathway to non-preferred agents when clinically necessary.

Step therapy requirements by payer segment

Commercial plans

Commercial step therapy for GLP-1s varies by plan design, formulary tier, and employer benefit election. Key patterns:

Aetna (CVS Health): For type 2 diabetes, Aetna typically covers Ozempic and Mounjaro with PA. Step therapy may require documented failure of metformin or another first-line oral antidiabetic. For weight management, Wegovy and Zepbound are subject to tighter controls; Aetna dropped Zepbound from several 2026 standard formularies while maintaining Wegovy on select plans.

Cigna (Evernorth): Cigna requires at least three months of a structured lifestyle modification program before initiating GLP-1 therapy for weight management. Within-class step therapy directs patients to preferred GLP-1s based on formulary tier; non-preferred agents require documented therapeutic failure of the preferred agent.

UnitedHealthcare: UHC's commercial plans typically require PA for all GLP-1s, with step therapy through preferred agents. The PreCheck MyScript tool allows providers to check pharmacy eligibility and PA requirements before prescribing, including step therapy prerequisites.

BCBS plans: Blue Cross Blue Shield plans vary significantly by licensee. Blue Cross of Massachusetts eliminated GLP-1 coverage for obesity on its standard formulary effective January 1, 2026, with no exceptions except for employer-purchased riders. Other BCBS plans (e.g., BCBS Texas, Florida Blue, CareFirst) maintain GLP-1 weight-loss coverage with PA and step therapy.

Independent Health (Western New York): Among the most restrictive commercial GLP-1 policies. Requires BMI ≥40 with two obesity-related comorbidities (or BMI ≥30 with history of stroke or MI), plus six months of documented lifestyle management participation. Zepbound is the preferred GLP-1; Wegovy and Saxenda are reserved for patients with documented medical reasons not to use Zepbound.

Medicaid

Medicaid GLP-1 step therapy policies are set at the state level. The November 2025 Penn LDI cross-sectional study published in the Journal of General Internal Medicine found that:

• 70% of state Medicaid PA policies specify the comorbid conditions that qualify for GLP-1 coverage
• Some states require two or more comorbidities — more restrictive than the FDA label
• Step therapy requirements vary significantly, with some states requiring documented failure of multiple agents

Pennsylvania Medicaid (2026): Pennsylvania's revised GLP-1 PA guidelines (effective March 2, 2026) establish a detailed step therapy hierarchy:

1. Preferred GLP-1s for diabetes: require a diagnosis of diabetes or a history of an antidiabetic drug (excluding metformin, SGLT-2 inhibitors, and drugs containing a GLP-1 RA) within the last 120 days
2. Non-preferred GLP-1s for diabetes: require documented therapeutic failure, contraindication, or intolerance to maximum FDA-approved doses of all preferred GLP-1 RAs
3. Weight management GLP-1s: require documented failure of specific agents in a defined sequence (Ozempic → Wegovy → Mounjaro → Zepbound)

NC Medicaid: Covers GLP-1s for weight management with BMI ≥30 or BMI ≥27 with comorbidity, requiring documented participation in a lifestyle modification program and PA.

California Medi-Cal: Effective January 1, 2026, Medi-Cal eliminated coverage for GLP-1s used exclusively for weight loss (Wegovy, Zepbound, Saxenda). GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity) remain covered with PA.

Medicare

Medicare Part D covers GLP-1s for FDA-approved diabetes indications with standard Part D cost sharing. The Medicare GLP-1 Bridge demonstration (launching July 1, 2026) expands coverage to GLP-1s for weight reduction for eligible beneficiaries with BMI ≥35 (or BMI ≥27 with qualifying comorbidities). Step therapy is not explicitly required under the Bridge, but beneficiaries must meet clinical criteria attested by the prescribing provider.

The step therapy exception workflow

When to file a step therapy exception

A step therapy exception is appropriate when the patient:

• Has a contraindication to the required first-line medication (e.g., severe renal impairment preventing metformin use; history of medullary thyroid carcinoma or MEN2 syndrome precluding all GLP-1s)
• Has a documented intolerance or adverse reaction to the preferred GLP-1 at therapeutic doses (e.g., severe nausea and vomiting persisting after dose adjustment and antiemetic trial)
• Has therapeutic failure of the preferred GLP-1 at maximum FDA-approved dose (e.g., inadequate glycemic control on Ozempic 2 mg; insufficient weight loss on Wegovy 2.4 mg after adequate trial duration)
• Has a formulary exclusion that makes the required step therapy drug unavailable (e.g., the preferred GLP-1 is not on the plan's formulary or is in shortage)

Step 1: Identify the step therapy requirement

Before writing the prescription, determine whether the payer requires step therapy for the requested GLP-1:

• Check the plan's formulary on the payer's provider portal or PBM website
• Use electronic tools: CoverMyMeds, Surescripts Benefit & Price Intelligence, or UHC's PreCheck MyScript
• Call the pharmacy benefit number on the patient's insurance card and ask: "Does this drug require step therapy? What is the preferred agent?"

Step 2: Gather exception documentation

The documentation required depends on the type of exception:

Contraindication exception:

• Chart note documenting the specific contraindication
• Relevant lab values (e.g., eGFR <30 for metformin contraindication)
• Genetic testing results if applicable (e.g., RET proto-oncogene for GLP-1 contraindication in MEN2)
• Clinical rationale explaining why the contraindication applies to the preferred agent but not to the requested agent

Intolerance or adverse reaction exception:

• Chart notes documenting the adverse reaction with dates, severity, and duration
• Documentation of dose adjustment attempts (e.g., titration down and re-titration)
• Documentation of interventions tried to manage the side effect (Pennsylvania Medicaid requires documentation that dietary changes, prescription antiemetics, and dose adjustments were tried over at least one month before accepting intolerance)
• Provider attestation that the adverse reaction is specific to the preferred agent and not expected with the requested agent

Therapeutic failure exception:

• Prescription fill history showing the patient was on the preferred GLP-1 at maximum dose for an adequate duration (typically 3–6 months)
• Clinical outcomes data: A1c values (for diabetes) or documented weight measurements (for obesity) showing inadequate response
• Provider attestation that the patient was adherent to the preferred agent and that therapeutic goals were not met despite adequate trial

Pennsylvania Medicaid defines therapeutic failure specifically: "Failure to achieve positive clinical response as defined by FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature."

Step 3: Submit the step therapy exception

Most payers accept step therapy exceptions through the same channels as prior authorization:

1. Electronic PA (ePA): Submit through CoverMyMeds, the EHR-integrated ePA workflow, or the payer's provider portal. Select "step therapy exception" as the request type. Pennsylvania Medicaid notes that the general PA form may be used "to initiate a step therapy exception."

2. Fax: Use the payer's specific step therapy exception form or general PA form with step therapy exception notation. Pennsylvania, for example, requires submission to the PA fax number listed in the provider handbook.

3. Phone: Some payers allow verbal step therapy exception requests with follow-up documentation.

Express Scripts/Evernorth provides a dedicated "Prior Authorization General Request Form" for initiating step therapy exceptions, and several states (Colorado, Oklahoma) have specific step therapy exception forms.

Step 4: Await determination

Under CMS-0057-F (effective January 1, 2026):

• Expedited requests: 72-hour decision timeline (for cases where delay would jeopardize the patient's health)
• Standard requests: 7-calendar-day decision timeline (reduced from 14 days under prior rules)
• AHIP pledges require participating insurers to provide clear explanations for PA determinations

Step 5: If denied, escalate

If the step therapy exception is denied:

1. Peer-to-peer review: Request a peer-to-peer conversation with the payer's medical director. This is the most effective escalation path for GLP-1 step therapy exceptions.
2. Formal appeal: File a formal appeal with additional documentation. Include published evidence supporting the clinical rationale for bypassing step therapy.
3. External review: If the internal appeal is denied, request an independent external review (required under the Affordable Care Act for most commercial plans).
4. State insurance commissioner: File a complaint with the state insurance commissioner if the denial appears to violate state step therapy laws.

Common GLP-1 step therapy scenarios

Scenario 1: Switching from Ozempic to Mounjaro for inadequate glycemic control

Patient has been on Ozempic 2 mg (maximum dose) for 4 months for type 2 diabetes. A1c remains at 8.2%, above the target of <7%. The plan requires step therapy through Ozempic (preferred) before Mounjaro (non-preferred).

Exception type: Therapeutic failure

Documentation needed:

• Prescription fill records showing 4+ months of Ozempic 2 mg
• A1c values: baseline (e.g., 9.1%), current (8.2%)
• Provider attestation of patient adherence
• Clinical rationale: inadequate glycemic control despite maximum-dose preferred agent

Scenario 2: Contralindication to metformin requiring direct GLP-1 initiation

Patient has type 2 diabetes with eGFR of 25 mL/min, which is a contraindication to metformin. The plan requires trying metformin before any GLP-1.

Exception type: Contraindication

Documentation needed:

• Lab results showing eGFR <30 mL/min
• Chart note documenting the renal impairment diagnosis
• Clinical rationale: metformin is contraindicated per FDA labeling at eGFR <30; GLP-1 (Ozempic) is appropriate per FDA labeling for T2D with renal impairment

Scenario 3: Intolerance to Wegovy injection requiring switch to Wegovy tablets

Patient experienced severe injection-site reactions to Wegovy injection that persisted across multiple injection sites and pen lots. The plan requires injectable Wegovy as preferred, with oral Wegovy (tablets) as non-preferred.

Exception type: Intolerance / adverse reaction

Documentation needed:

• Chart notes documenting injection-site reactions with dates and severity
• Documentation of attempts to mitigate (rotation of injection sites, different pen lots)
• Provider attestation that the same active ingredient in oral form is expected to resolve the injection-specific adverse reaction
• Note: This is a nuanced exception because the active ingredient is the same (semaglutide). The provider must document that the reaction is to the injection device/formulation, not to the active ingredient.

Scenario 4: Weight management GLP-1 step therapy through Saxenda before Wegovy

Patient with BMI 33 and hypertension seeks Wegovy. Plan requires trial of Saxenda (liraglutide 3 mg) before Wegovy (semaglutide 2.4 mg). Patient took Saxenda for 5 months and lost only 2.3% of body weight.

Exception type: Therapeutic failure

Documentation needed:

• Prescription fill records for Saxenda 3 mg, 5+ months
• Documented weight measurements: baseline weight, current weight, percentage change
• Clinical rationale: <5% weight loss after 5 months on maximum-dose Saxenda constitutes therapeutic failure; Wegovy has superior efficacy in clinical trials (STEP 1: ~15% weight loss vs. SCALE: ~5–8% for Saxenda)

Practical tips for step therapy exceptions

1. Document proactively. At every GLP-1 appointment, record weight, BMI, A1c (if applicable), side effects, dose adjustments, and therapeutic response. This creates the paper trail needed for future step therapy exceptions.

2. Know the preferred agent hierarchy. Before prescribing, check which GLP-1 is preferred on the patient's specific plan. Many payers use Express Scripts National Preferred Formulary or CVS Caremark formulary, which designate preferred GLP-1s by tier.

3. Use electronic tools. ePA platforms like CoverMyMeds can auto-populate step therapy exception fields and route them to the correct payer. Surescripts data shows automated PA workflows reduce GLP-1 PA processing time from 15–20 minutes to 0.5–3 minutes.

4. Request peer-to-peer early. If the initial exception is denied, a peer-to-peer review with the payer's medical director is often more effective than a written appeal alone. Prepare a 2–3 minute summary of why step therapy is inappropriate for this specific patient.

5. Track approval timelines. Under CMS-0057-F, payers must meet 72-hour (expedited) and 7-day (standard) decision timelines. If the payer exceeds these timelines, document the delay and file a complaint.

6. Check for state protections. Several states have enacted step therapy reform laws that limit the duration of step therapy requirements, establish clear exception criteria, and prohibit step therapy that contradicts FDA labeling. Colorado's step therapy exception form is a model template.

7. Negotiate the step therapy duration. The ICER white paper Affordable Access to GLP-1 Obesity Medications (April 2025) recommends that step therapy through earlier obesity medications should use a "reasonable 3 to 4 month period" to determine whether less expensive options are working adequately before allowing patients to begin GLP-1 treatment. Clinical experts advised that 6-month trial periods are "far longer than necessary." If your payer requires a 6-month lifestyle or prior-therapy trial, cite the ICER recommendation in your step therapy exception.

Sources

• Pennsylvania Department of Human Services. GLP-1 Receptor Agonists Prior Authorization Guideline Revisions. MAAC Briefing Document. January 22, 2026, revised March 2, 2026. (pa.gov)
• Klebanoff MJ, Chetty AK, Doshi J. Medicaid Coverage and Prior Authorization for Antiobesity GLP-1 Receptor Agonists: A Cross-Sectional Study of State Policies. Journal of General Internal Medicine. November 21, 2025. (ldi.upenn.edu)
• CMS. Information for Medicare Beneficiaries — Medicare GLP-1 Bridge. 2026. (cms.gov)
• KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid. 2026. (kff.org)
• KFF. Medicaid Coverage of and Spending on GLP-1s. 2026. (kff.org)
• IntuitionLabs. The ePA Process for GLP-1 Drugs: A Workflow Guide. 2025. (intuitionlabs.ai)
• Evernorth / Express Scripts. Prior Authorization Resources — Step Therapy Exception Forms. 2026. (evernorth.com)
• Surescripts. Meaningful Innovation Starts with Collaboration — Prior Authorization Automation Data. 2026. (surescripts.com)
• Truveris. How Pharmacy Plans Are Managing GLP-1 Coverage in 2025. (truveris.com)
• Word & Brown. Weight Loss Drugs (GLP-1) Insurance Coverage — Payer Formulary Summary. Updated March 17, 2026. (wordandbrown.com)
• Independent Health. GLP-1 Medications and Preauthorization. 2025. (independenthealth.com)
• ICER. Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Coverage Policy. April 2025. (icer.org)